Werewolf Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the and

Condensed Consolidated Statements of Operations (unaudited)

(amounts in thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Revenue:
Collaboration revenue	$—	$1,143	$—	$1,885
Operating expenses:
Research and development	13,143	15,271	26,263	28,179
General and administrative	4,399	4,832	9,270	9,828
Total operating expenses	17,542	20,103	35,533	38,007
Operating loss	(17,542)	(18,960)	(35,533)	(36,122)
Other (expense) income:
Interest income	850	1,793	1,847	3,766
Interest expense	(1,301)	(1,142)	(2,564)	(2,145)
Loss on extinguishment of debt	—	(553)	—	(553)
Other income, net	11	1,613	179	1,612
Total other (expense) income	(440)	1,711	(538)	2,680
Net loss	$(17,982)	$(17,249)	$(36,071)	$(33,442)
Net loss per common share, basic	$(0.40)	$(0.40)	$(0.80)	$(0.79)
Net loss per common share, diluted	$(0.40)	$(0.43)	$(0.80)	$(0.82)
Weighted-average common shares outstanding, basic	44,981,746	43,521,406	44,904,880	42,564,342
Weighted-average common shares outstanding, diluted	44,981,746	44,043,184	44,904,880	42,825,231

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.